Evidence map›Paper›PMID 40382488›Full record

ArticleEuropean radiology2025

Temporal evolution of the LI-RADS radiation treatment response assessment on multiphase CT/MRI in patients undergoing selective internal radiation therapy for hepatocellular carcinoma.

Hong Wei, Hanyu Jiang, Jeongin Yoo, Jae Hyun Kim, Hyo-Jin Kang, Yuanan Wu, Rongbo Liu, Hyo-Cheol Kim, Jeong Min Lee

Abstract read
In one paragraph

Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. The value ofEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Hong Wei *Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.
Hanyu Jiang *Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.
Jeongin YooDepartment of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.
Jae Hyun KimDepartment of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.
Hyo-Jin KangDepartment of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.
Yuanan WuBig Data Research Center, University of Electronic Science and Technology of China, Chengdu, China.
Rongbo LiuDepartment of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.
Hyo-Cheol KimDepartment of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.
Jeong Min LeeDepartment of Radiology, Seoul National University Hospital, Seoul, Republic of Korea. jmsh@snu.ac.kr.ORCID http://orcid.org/0000-0003-0561-8777

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess the temporal evolution and interobserver agreement of the early categories per the liver imaging reporting and data system (LI-RADS) radiation treatment response assessment (TRA) algorithm in patients receiving selective internal radiation therapy (SIRT) with Yttrium-90 for hepatocellular carcinoma (HCC). MATERIALS AND

methodsThis single-center retrospective study included consecutive patients with treatment-naïve HCC who underwent serial contrast-enhanced CT/MRI before and after SIRT. Three masked radiologists independently evaluated response at 3-6 months. Another senior radiologist assessed response at 9, 12, 15, 18, 21, 24, and > 24 months after comprehensive review of available clinical-radiological information.

results65 patients (mean age, 66.7 ± 11.2 years; 48 men) were included. At 3-6 months after SIRT, 47.7% (31/65) of lesions were assigned to the nonprogressing category, and the remaining 52.3% (34/65) to the nonviable category. Among early nonprogressing lesions, 64.5% (20/31) regressed to the nonviable category, 25.8% (8/31) remained nonprogressing, and 9.7% (3/31) evolved into the viable category at ≥ 12 months. The nonprogressing category decreased in number over time, with 61.3% (19/31) conversion to the nonviable category at 9 months. Among the early nonviable lesions, 91.2% (31/34) remained nonviable at ≥ 12 months, and 8.8% (3/34) evolved into the viable category. Agreement for the 3-6 months LR-TR category assignment was moderate (kappa = 0.46) with CT but almost perfect (kappa = 0.85) with MRI.

conclusionsSIRT induced a delayed and sustained response in the majority of HCC patients after ≥ 12 months. MRI demonstrated superior agreement over CT in assessing response at 3-6 months. KEY POINTS: Question Tumor response to SIRT can change; there is limited evidence on the evolution of the imaging appearance of HCC following SIRT. Findings Sixty-four and five-tenths of early nonprogressing lesions regressed to nonviable, and 91.2% of early nonviable lesions remained free of viability. LR-TR category assignment agreement was moderate with CT but almost perfect with MRI. Clinical relevance SIRT induced a delayed and sustained response in HCC, underscoring the necessity of dynamic evaluation of long-term changes in treated lesions. MRI with subtraction imaging may be preferred over CT for long-term monitoring, which may help prevent premature retreatment decisions.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMagnetic Resonance ImagingTomography, X-Ray ComputedAgedAlgorithmsContrast MediaFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeYttrium RadioisotopesContrast MediaYttrium RadioisotopesCarcinoma (hepatocellular)Computed tomographyLiver imaging reporting and data system treatment responseMagnetic resonance imagingSelective internal radiation therapy

Identifiers

PMID40382488
PMCPMC12559135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.